the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer)

Non-small Cell Lung Cancer Clinical Trial

Official title:

Evaluation of the Efficacy of Domestic Gefitinib Tablets in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients Using a Multicenter, Randomized, Positive Drug Gefitinib Pharmacodynamics and Pharmacodynamics

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03264794
• Other study ID #: CTTQ-20161017
• Status: Not yet recruiting
• Phase: Phase 4
• First received: July 3, 2017
• Last updated: August 28, 2017
• Start date: August 2017
• Est. completion date: June 2022

Study information

• Verified date: January 2017
• Source: Jiangsu Famous Medical Technology Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

1. Gefitinib CTTQ production gefitinib and erlotinib sheet AstraZeneca imatinib sheet (trade name: Iressa ®) comparison, human pharmacokinetics and relative bioavailability of comparative studies which examine people in vivo pharmacokinetic behavior, provide the basis for clinical use.

2. Evaluation CTTQ gefitinib imatinib sheet production efficacy and safety of Chinese patients with locally advanced or metastatic non-small cell lung cancer.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 100
• Est. completion date: June 2022
• Est. primary completion date: December 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients volunteered to participate in this study, signed informed consent;

2. =18 years old; ECOG PS score: 0 ~ 1; expected survival period of more than 3 months;

3. patients with locally advanced or metastatic non-small cell lung cancer diagnosed by histology or cytology, who can not receive radical surgery or radiotherapy; patients with measurable lesions(according to RECIST criteria);

4. Detection of EGFR-positive exon 19 deletion or exon 21 (L858R) mutation was performed by providing a detectable specimen (tissue or cancerous pleural effusion) prior to enrollment;

5. The main organ function within 7 days before treatment, meet the following criteria:

(1) blood routine examination criteria (14 days without blood transfusion): A) hemoglobin= 90g / L; B) neutrophil absolute = 1.5 × 109 / L; C) platelet =80 × 109 / L (2) biochemical tests to meet the following criteria: A) total bilirubin = 1.5 times the upper limit of normal (ULN); B) alanine aminotransferase and aspartate aminotransferase AST = 2.5ULN, such as liver metastasis, ALT and AST = 5ULN; C) serum creatinine = 1.5ULN or creatinine clearance = 60ml / min; (3) Doppler ultrasound evaluation: left ventricular ejection fraction (LVEF) = normal low (50%).

6.Women of childbearing age should agree that contraceptive measures (such as intrauterine devices, birth control pills or condoms) must be used within the study period and within 6 months after the end of the study; serum or urine pregnancy test is negative within 7 days prior to enrollment, And must be non-lactating patients; men should agree to patients who have contraceptive use during the study period and six months after the end of the study period.

Exclusion Criteria:

1. patients who have previously used EGFR-TKI drugs;

2. small cell lung cancer (including small cell carcinoma and non-small cell carcinoma mixed lung cancer);

3. central type, with empty lung squamous cell carcinoma, or with non-small cell lung cancer with hemoptysis (> 50 ml / day) 4.5 years or at the same time with other malignancies, cured cervical carcinoma in situ, non-melanoma skin cancer and superficial bladder tumor except [Ta (non-invasive tumor), Tis (carcinoma in situ ) And T1 (tumor infiltrating basement membrane)];

5.Whole-body antitumor therapy was planned within 4 weeks prior to randomization or during the course of this study, including cytotoxic therapy, signal transduction inhibitors, immunotherapy (or use of mitogen at 6 weeks prior to administration of the test drug) C); 6.patients with symptomatic or unstable brain metastases; 7.patients with any severe and / or uncontrolled disease, including: A) cirrhosis, acute or active hepatitis; B) history of immunodeficiency, including HIV-positive or other acquired, congenital immunodeficiency disease, or history of organ transplantation; C) patients with seizures and who need treatment; 8.active or uncontrollable serious infection (=CTC AE Level 2 infection); 9.with a history of mental illness and can not quit or have mental disorders; 10.participated in other anti-tumor drug clinical trials within four weeks; 11.According to the judge's judgment, there is an impact on the absorption of oral drugs or serious harm to the safety of patients is not suitable for participation in the study of the situation.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-small Cell Lung Cancer

Intervention

Drug:
• Gefitinib Tab (CTTQ),First medication;Gefitinib Tab (CTTQ),From the 8th day of trial
Gefitinib Tab (CTTQ),First medication,250mg;
• Gefitinib tablets (Yi Ruisha),First medication
Gefitinib tablets (Yi Ruisha),First medication,250mg;
• Gefitinib Tab 250 MG(CTTQ),From the 8th day of trial.
From the 8th day of the experiment, two groups of subjects were treated with Gefitinib(CTTQ)

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Jiangsu Famous Medical Technology Co., Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Gefitinib plasma concentration	After the use of gefitinib to reach the highest plasma concentration	0hour before administration and 1, 2, 3, 4, 5, 6, 7, 8,9,13,24,48,72,120,168 16 hour time points after administration
Primary	Tmax time	Taking the time required for the concentration of gefitinib to reach the peak	0hour before administration and 1, 2, 3, 4, 5, 6, 7, 8,9,13,24,48,72,120,168 16 hour time points after administration
Primary	AUC0-t	The area between the axis of the coordinate and the time drug concentration curve	0hour before administration and 1, 2, 3, 4, 5, 6, 7, 8,9,13,24,48,72,120,168 16 hour time points after administration
Primary	t 1/2	The time required for gefitinib to decrease by half the highest concentration in plasma	0hour before administration and 1, 2, 3, 4, 5, 6, 7, 8,9,13,24,48,72,120,168 16 hour time points after administration
Primary	F	Gefitinib absorbs the relative amount of blood into the cycle	0hour before administration and 1, 2, 3, 4, 5, 6, 7, 8,9,13,24,48,72,120,168 16 hour time points after administration